Prime Medicine, Inc.
Close on Oct 19, 2026
- Market cap
- $678.77M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $1.12M | $-0.41 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 1, 2024 | Before market open | – | – | – |
Press releases
Announcements Prime Medicine filed with the SEC
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
19 >80% hepatocytes edited Hepatic copper concentration returns to wild-type levels at eight weeks Copper excreted normally through the feces at four weeks PM577 Efficiently Corrects the H1069Q Mutation and Completely Restores Wild- Type Copper Concentration In Vivo
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
15Delivering on the promise of Prime Editing Wilson Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
19Confidential | Alpha-1 Antitrypsin Deficiency (AATD)
Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
19Confidential | Alpha-1 Antitrypsin Deficiency (AATD)
Results of operations · Other events · EX-99.1 to Form 8-K
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
12| Hematology, Immunology and Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Unveils Strategically Focused Pipeline
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
37 primemedicine.com Delivering on the promise of Prime Editing Appendix
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Healthcare Conference January 2024 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26 th Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K/A
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
Regulation FD disclosure · EX-99.2 to Form 8-K